Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with induction chemotherapy and chemoradiotherapy followed by maintenance atezolizumab in unresectable stage III NSCLC
2020-004459-33Phase 2Active
- Sponsor
- Fundación GECP
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Primary endpoint: Progression-free survival at 12 months. Started Sep 2021; status: active.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-004459-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004459-33.